INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,435,937 | -14.7% | 46,764 | +3.7% | 0.02% | -5.9% |
| Q2 2023 | $2,855,795 | +19.3% | 45,101 | +2.0% | 0.02% | +6.2% |
| Q1 2023 | $2,394,405 | +4.4% | 44,218 | +2.0% | 0.02% | 0.0% |
| Q4 2022 | $2,293,447 | +13.3% | 43,338 | -0.4% | 0.02% | +6.7% |
| Q3 2022 | $2,024,000 | -17.3% | 43,496 | +1.4% | 0.02% | -11.8% |
| Q2 2022 | $2,448,000 | +0.3% | 42,881 | +7.5% | 0.02% | +30.8% |
| Q1 2022 | $2,441,000 | +24.2% | 39,899 | +6.2% | 0.01% | +30.0% |
| Q4 2021 | $1,966,000 | +36.3% | 37,560 | -2.9% | 0.01% | +25.0% |
| Q3 2021 | $1,442,000 | -10.8% | 38,683 | -2.3% | 0.01% | +60.0% |
| Q2 2021 | $1,617,000 | +23.2% | 39,602 | +2.4% | 0.01% | 0.0% |
| Q1 2021 | $1,312,000 | +7.0% | 38,670 | +0.3% | 0.01% | 0.0% |
| Q4 2020 | $1,226,000 | +22.2% | 38,568 | -1.3% | 0.01% | 0.0% |
| Q3 2020 | $1,003,000 | +16.2% | 39,088 | +16.2% | 0.01% | +25.0% |
| Q2 2020 | $863,000 | +80.2% | 33,638 | +7.8% | 0.00% | +33.3% |
| Q1 2020 | $479,000 | -49.9% | 31,197 | +11.9% | 0.00% | -25.0% |
| Q4 2019 | $957,000 | +355.7% | 27,885 | -0.8% | 0.00% | +300.0% |
| Q3 2019 | $210,000 | -42.9% | 28,120 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $368,000 | +5.7% | 28,315 | -0.9% | 0.00% | 0.0% |
| Q1 2019 | $348,000 | +3.6% | 28,562 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $336,000 | -47.9% | 29,488 | -0.8% | 0.00% | -50.0% |
| Q3 2018 | $645,000 | +25.0% | 29,715 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $516,000 | -9.6% | 29,178 | +7.5% | 0.00% | 0.0% |
| Q1 2018 | $571,000 | +37.9% | 27,130 | -5.1% | 0.00% | +100.0% |
| Q4 2017 | $414,000 | +16.0% | 28,590 | +26.3% | 0.00% | 0.0% |
| Q3 2017 | $357,000 | +37.3% | 22,635 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $260,000 | -24.2% | 20,943 | -0.9% | 0.00% | 0.0% |
| Q1 2017 | $343,000 | +15.1% | 21,130 | +7.1% | 0.00% | 0.0% |
| Q4 2016 | $298,000 | -99.9% | 19,734 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $301,539,000 | -60.7% | 19,786 | +0.2% | 0.00% | -66.7% |
| Q2 2016 | $766,928,000 | +78.8% | 19,756 | +28.0% | 0.00% | +50.0% |
| Q1 2016 | $429,000,000 | -37.3% | 15,438 | +21.5% | 0.00% | -33.3% |
| Q4 2015 | $684,000,000 | +134017.6% | 12,709 | -0.2% | 0.00% | +50.0% |
| Q3 2015 | $510,000 | -99.9% | 12,731 | +0.1% | 0.00% | 0.0% |
| Q2 2015 | $406,276,000 | +58.2% | 12,716 | +18.3% | 0.00% | +100.0% |
| Q1 2015 | $256,734,000 | +35.3% | 10,751 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $189,755,000 | +23.8% | 10,751 | -3.8% | 0.00% | 0.0% |
| Q3 2014 | $153,250,000 | -18.7% | 11,178 | -0.1% | 0.00% | 0.0% |
| Q2 2014 | $188,579,000 | – | 11,185 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |